Loading
BMS-986511 / Major Depressive Disorder · Phase 2 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a trial registration for a Phase 2 study of BMS-986511, a novel agent in adults with major depressive disorder, comparing drug to placebo on the HDRS-17 over 57 days. No results are yet available; the study has not begun recruitment. The record documents the planned design but provides insufficient detail on methodology to assess bias risk.
Phase 2, Interventional, Randomized, Sequential, Quadruple masking, Treatment purpose. Major Depressive Disorder; age from 18 Years; to 65 Years. Intervention: BMS-986511: Dose A; BMS-986511: Dose B; Placebo. Compared with: Placebo. n = 200. 26 sites: United States, Czechia.
This is a trial registration for a Phase 2 study of BMS-986511, a novel agent in adults with major depressive disorder, comparing drug to placebo on the HDRS-17 over 57 days. No results are yet available; the study has not begun recruitment. The record documents the planned design but provides insufficient detail on methodology to assess bias risk.
No efficacy, safety, or tolerability data are available.
The source did not state who this applies to in practice.
This is a Phase 2 trial registration with no reported results; the study is not yet recruiting and represents early-stage evaluation of a novel agent.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07772531). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Major Depressive Disorder. Interventions: DRUG: BMS-986511; DRUG: Placebo. Primary outcome measures: Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score , Up to Day 57. Brief summary: A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.